other material
confidence high
sentiment positive
materiality 0.75
Gilead reports EVOKE-02 Phase 2 data: SG+Pembro 56% ORR in 1L mNSCLC
GILEAD SCIENCES, INC.
- ORR 69% in PD-L1 TPS≥50% (Cohort A), 44% in <50% (Cohort B); overall ORR 56%.
- Median DOR not reached; 6-month DOR rate 88% in both cohorts.
- Any-grade TEAEs 100%, Grade≥3 70%; 1 treatment-related death (sepsis).
- Data inadvertently posted early by IASLC; Gilead discloses via 8-K.
- Phase 3 EVOKE-03 comparing SG+Pembro vs Pembro monotherapy is ongoing.